Obicetrapib and Ezetimibe Combination Treatment and Fixed Dose Pharmaceutical Compositions

Abstract: the present disclosure relates to stable pharmaceutical compositions comprising fixed dose combination of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. the disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of such fixed dose combinations, for preparation of medicaments and method of treatment of subjects requiring reduction in ldl-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

Inventor(s): Joanne Lesley CRAIG, Sheng CUI, Michael Harvey DAVIDSON, Marc DITMARSCH, Johannes Jacob Pieter KASTELEIN, Andreas René RÖTHELLI, Christopher J. BORTHS, Muneki KISHIDA, Valeriya Nikolayevna SMOLENSKAYA

CPC Classification: A61K31/506 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles ; soap compositions ))

Search for rejections for patent application number 20250186442